非吸烟相关肺腺癌细胞全基因组分析揭示EGFR突变肿瘤中常见RB1重排与组织学转化相关
研究建立非吸烟相关转移性肺腺癌患者来源细胞培养,对两对EGFR突变TKI耐药前后配对细胞行全外显子及RNA测序,并在独立原发肺腺癌队列验证。发现除已知非吸烟相关改变外,存在ATF7IP等新突变及家族性癌症基因胚系突变;治疗初治EGFR突变肺腺癌中RB1失活(多为复杂基因内重排)过表达,耐药后出现SCLC/LuSCC转化,与RB1失活及获得性EGFR-T790M或FGFR3-TACC3融合一致。
要点
- 非吸烟肺腺癌存在ATF7IP失活(原发5%)及家族性癌症基因胚系突变。
- 治疗初治EGFR突变肺腺癌中RB1失活(复杂重排)过表达,耐药后出现SCLC/LuSCC转化。
- RB1失活或可预测肺腺癌向更具侵袭性类型转化的风险。
核心结论
- 非吸烟相关肺腺癌存在值得进一步探索的复发性改变,部分起源于癌症易感综合征。
- EGFR突变肿瘤中经复杂重排的RB1失活优先发生,似在生长抑制压力下促进SCLC/LuSCC转化。
- RB1失活或可预测肺腺癌向更具侵袭性类型转化的风险,或需纳入非吸烟相关肺腺癌患者临床管理。
研究设计与样本
- 建立非吸烟相关转移性肺腺癌患者来源癌细胞培养,包括两对EGFR突变TKI耐药前后配对细胞。
- 行全外显子及RNA测序描绘基因组结构,并在独立原发肺腺癌队列验证。
主要发现
- 除已知非吸烟相关改变(RET、ALK、EGFR、ERBB2)外,发现新融合及复发性突变基因,包括基因表达调控因子ATF7IP,在原发肺腺癌病例中5%失活。
- 发现显性家族性癌症基因胚系突变,提示部分非吸烟相关肺腺癌起源中遗传易感性的重要性。
- 治疗初治EGFR突变肺腺癌中RB1失活改变过表达,多通过复杂基因内重排实现。
- 三个EGFR突变和一个EGFR野生型肿瘤分别对EGFR-TKI和化疗获得耐药,再活检组织学显示小细胞肺癌/鳞状细胞癌(SCLC/LuSCC)转化。
- 上述特征与RB1失活及EGFR突变肿瘤中获得性EGFR-T790M突变或FGFR3-TACC3融合一致。
临床怎么用
- 非吸烟相关肺腺癌患者管理或需考虑RB1失活状态以评估组织学转化风险。
- 对EGFR突变肺腺癌耐药后再活检关注SCLC/LuSCC转化及RB1失活、EGFR-T790M或FGFR3-TACC3融合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The etiology and the molecular basis of lung adenocarcinomas (LuADs) in nonsmokers are currently unknown. Furthermore, the scarcity of available primary cultures continues to hamper our biological understanding of non-smoking-related lung adenocarcinomas (NSK-LuADs). PATIENTS AND METHODS: We established patient-derived cancer cell (PDC) cultures from metastatic NSK-LuADs, including two pairs of matched EGFR-mutant PDCs before and after resistance to tyrosine kinase inhibitors (TKIs), and then performed whole-exome and RNA sequencing to delineate their genomic architecture. For validation, we analyzed independent cohorts of primary LuADs. RESULTS: In addition to known non-smoker-associated alterations (e.g. RET, ALK, EGFR, and ERBB2), we discovered novel fusions and recurrently mutated genes, including ATF7IP, a regulator of gene expression, that was inactivated in 5% of primary LuAD cases. We also found germline mutations at dominant familiar-cancer genes, highlighting the importance of genetic predisposition in the origin of a subset of NSK-LuADs. Furthermore, there was an over-representation of inactivating alterations at RB1, mostly through complex intragenic rearrangements, in treatment-naive EGFR-mutant LuADs. Three EGFR-mutant and one EGFR-wild-type tumors acquired resistance to EGFR-TKIs and chemotherapy, respectively, and histology on re-biopsies revealed the development of small-cell lung cancer/squamous cell carcinoma (SCLC/LuSCC) transformation. These features were consistent with RB1 inactivation and acquired EGFR-T790M mutation or FGFR3-TACC3 fusion in EGFR-mutant tumors. CONCLUSIONS: We found recurrent alterations in LuADs that deserve further exploration. Our work also demonstrates that a subset of NSK-LuADs arises within cancer-predisposition syndromes. The preferential occurrence of RB1 inactivation, via complex rearrangements, found in EGFR-mutant tumors appears to favor SCLC/LuSCC transformation under growth-inhibition pressures. Thus RB1 inactivation may predict the risk of LuAD transformation to a more aggressive type of lung cancer, and may need to be considered as a part of the clinical management of NSK-LuADs patients.
引用
- Pros E, Saigi M, Alameda D, et al. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors. Ann Oncol. 2020. PMID: 31959344. doi:10.1016/j.annonc.2019.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。